The split-beam hydro-acoustics surveys were conducted to learn about the diel migration and distribution characters of Toxabramis houdermeri and to assess its current abundance in Baise Reservoir of China in October 2013. The study revealed the average density of T. houdermeri was 258 individuals/1000 m³, and gradually increased from downstream, through middle to upstream (203 individuals/1000 m³, 252 individuals/1000 m³ and 318 individuals/1000 m³, respectively). The study also showed that the target species always distributed in the 2-42 m water layer during the daytime, before migrating upward around dusk which led the fish density to sit in the 2-12 m water layer, to reaching a peak value of 1740 individuals/1000 m³ during the night. Finally, the fish volume density was found to positively correlate with the concentration of chlorophyll, dissolved oxygen (DO) and pH value in their studied areas. In conclusion, the result presented that T. houdermeri preferred a relatively higher average chlorophyll concentration of 3.58 ug/L DO od 6,33 mg/L, and pH of 7.96 in the upstream and upper layers of Baise Reservoir.
This mini-review aims to introduce the association between Secretory clusterin/apolipoprotein J (sCLU) and diverse musculoskeletal diseases. A comprehensive review of the literature was performed to identify basic science and clinical studies, which implied the therapeutic and prognostic role of sCLU in diverse musculoskeletal diseases. sCLU is a multifunctional glycoprotein that is ubiquitously expressed in various tissues and is implicated in many pathophysiological processes. Dysregulated expression of sCLU had been reported to be assocaited with proliferative or apoptotic molecular processes and inflammatory responses, which participated in many pathophysiological processes such as degenerative musculoskeletal diseases including ischemic osteonecrosis, osteoarthritis (OA) and degenerative cervical myelopathy (spinal cord injury), neoplastic musculoskeletal diseases, inflammatory and autoimmune musculoskeletal diseases including Rheumatoid arthritis (RA), joint damage induced by Brucella abortus, Sjogren's syndrome, idiopathic inflammatory myopathies, muscle glucose metabolism, insulin sensitivity and traumatic musculoskeletal diseases. Recent findings of sCLU in these musculoskeletal diseases provides insights on the therapeutic and prognostic role of sCLU in these musculoskeletal diseases. sCLU may serve as a promising therapeutic target for ischemic osteonecrosis, OA and spinal cord injury as well as a potential prognostic biomarker for OA and RA. Moreover, sCLU could act as a prognostic biomarker for osteosarcoma (OS) and a promising therapeutic target for OS resistance. Although many studies support the potential therapeutic and prognostic role of sCLU in some inflammatory and autoimmune-mediated musculoskeletal diseases, more future researches are needed to explore the molecular pathogenic mechanism mediated by sCLU implied in these musculoskeletal diseases.